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Transforming Growth Factor-b in Liver
Cancer Stem Cells and Regeneration
Shuyun Rao,1 Sobia Zaidi,1 Jaideep Banerjee,1 Wilma Jogunoori,1 Raul Sebastian,1 Bibhuti Mishra,1,3 Bao-Ngoc Nguyen,1
Ray-Chang Wu,2 Jon White,3 Chuxia Deng,1,4 Richard Amdur,1 Shulin Li,5 and Lopa Mishra1,3
Cancer stem cells have established mechanisms that contribute to tumor heterogeneity as well as resistance to therapy.
Over 40% of hepatocellular carcinomas (HCCs) are considered to be clonal and arise from a stem-like/cancer stem cell.
Moreover, HCC is the second leading cause of cancer death worldwide, and an improved understanding of cancer stem
cells and targeting these in this cancer are urgently needed. Multiple studies have revealed etiological patterns and multiple
genes/pathways signifying initiation and progression of HCC; however, unlike the transforming growth factor b (TGF-b)
pathway, loss of p53 and/or activation of b-catenin do not spontaneously drive HCC in animal models. Despite many
advances in cancer genetics that include identifying the dominant role of TGF-b signaling in gastrointestinal cancers, we
have not reached an integrated view of genetic mutations, copy number changes, driver pathways, and animal models that
support effective targeted therapies for these common and lethal cancers. Moreover, pathways involved in stem cell trans-
formation into gastrointestinal cancers remain largely undefined. Identifying the key mechanisms and developing models
that reflect the human disease can lead to effective new treatment strategies. In this review, we dissect the evidence
obtained from mouse and human liver regeneration, and mouse genetics, to provide insight into the role of TGF-b in reg-
ulating the cancer stem cell niche. (Hepatology Communications 2017; 00:000–000)
Introduction
C
ancer stem cells have established mecha-
nisms that contribute to tumor heterogene-
ity as well as resistance to therapy.(1-4) Yet
to date, the switches involved in stem cell transfor-
mation in the liver and the definitive role of key
pathways involved in liver regeneration and cancer
remain partially understood. Multiple studies have
revealed etiological patterns and multiple genes/
pathways signifying initiation and progression of
HCC. These pathways include CTNNB1/WNT-b-
catenin, TPp53, ARID1/2s, HGF/c-Met, and
vascular endothelial growth factor/angiogenic signal-
ing.(5-12) However, unlike the transforming growth
factor b (TGF-b) pathway, loss of p53 and/or activa-
tion of b-catenin do not spontaneously drive HCC
in animal models.(13-15)
Primary cancer of the liver (HCC) currently remains
among the most prevalent and lethal cancers, with 17%
5-year survival rate (2007–2013).(2,16-18) Drug resistance is
one of the causal factors for therapy failure and is associated
with the existence of tumor-like stem cells.(15) Yet driving
pathways and mechanistic insight into stem cell transfor-
mation, leading to targeted therapeutics, remain poorly
understood for these cancers. We review insight into how
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TGF-b drives these cancers and controls the switch from
normal stem cells to cancer through mechanistic insight of
mouse genetic models.(13,14) TGF-b serves as an essential
regulator of cell polarity, growth, differentiation, lineage
specificity, tumor suppression, as well as tumor promotion
in multiple cell types(13,19) (Figs. 1–3). Yet the significance
of dichotomy in function remains unclear for the liver and
gastrointestinal system. Defective TGF-b signaling is
implicated in multiple cancers due to frequent somatic
mutations or deregulation of its components, such as
Smad3, Smad4, and TGF-b receptors 1 and 2 (TBRI and
TBRII).(15,20,21) Smads are the intracellular mediators of
TGF-b signaling,(21-24) and their function is modulated by
adaptor proteins such as the Smad anchors and signal trans-
ducers, filamin, andmicrotubules,(25,26) as well as E3 ligases
such as SMURFs, Ski, PRAJA, Sno, and others.
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FIG. 1. TGF-b serves as an essential regulator of cell polarity, growth, differentiation, lineage specificity, tumor suppression, and
tumor promotion in multiple cell types.
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Traditionally, TGF-b has been considered to be mainly
prominent during the termination phase of liver regenera-
tion. However, several TGF-b–associated genes have
important roles throughout the three phases of liver regen-
eration and focusing on the temporal fluctuations of these
TGF-b–associated partners can provide an insight into
their function. This review addresses the role of “core”
TGF-b pathway–related genes (based on a literature
search) that are grouped into five different categories,
including TGF-b “receptors,” “ligands,” “receptor sub-
strates,” “adaptors,” and “inhibitory SMADs.” These genes
are TGF-b1-3, TBRIII, TGF-bRAP1, BMP1-7,
BMP9,10, BMP15, BMPR1A, BMPR1B, BMPR2,
SMAD1-7, SMAD9, SPTBN1 (b2SP), ACVR1,
ACVR1B, ACVR1C, ACVR2A, ACVR2B, ACVRL1,
ZFYVE9, INHA, INHBA, INHBB, INHBC, INHBE,
GDF1, GDF11, and NODAL. In addition, other mole-
cules, including E3 ligases, are also associated upstream or
downstream of the TGF-b pathway and correlate their
expression levels with TGF-b pathway activity such as SKI,
SMURF1-2, ITCH, ITIH4, SARA, b2SP, ELF1-5,
PRAJA1-2, MYC, TERT, RUNX, CTCF, ALDH2,
IL-6, STAT3, TWIST1-2, ZEB1, CDK4, TGIF1-2,
STRAP, and SNAI1-2.
Liver Stem Cells and
TGF-b: Evidence From
Mouse Knockout, Lineage
Studies, and Human Liver
Regeneration
Currently, at least three stem cell populations are
known to exist in both mouse(27) and human adult
liver(28): 1) pericentral Axin21 hepatocytes that can
regenerate liver in normal homeostasis(29); 2) periportal
cells positive for Lgr5(30); 3) Prom11 liver stem cells
that are located within or adjacent to the Krt191 bile
duct epithelium.(31) Human periportal cells also label
for octamer 3/4 (Oct3/4), b2 spectrin (b2SP), and
TBRII in both human and mouse liver regenera-
tion.(27,28,32) Through previous studies in human liver
donor and liver transplant specimens that represent
human liver regeneration, as well as fulminant hepatic
failure, putative liver progenitor/stem cell expansion
has been observed during massive hepatic necrosis with
fibrosis as well as submassive hepatic necrosis with
hepatocytic lineage. The observation of fibrosis in the
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FIG. 2. List of genes that has
been identified to be important in
liver cancer stem cell or normal
stem cell function.
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massive hepatic necrosis group may indicate aberrant
TGF-b signaling, which is not observed in the sub-
massive necrosis group where a few hepatocytes are
observed.(33) In human liver regeneration, liver progen-
itor/stem cells are observed along the pericentral vein
early in regeneration (before 6 weeks following post
transplantation), and later at the portal tracts (6
weeks post transplantation)(28) (Fig. 4). Anti-Oct4 and
Nanog are observed to label cells as early as the first 1-
3 weeks, representing early liver regeneration.(28) These
putative progenitor cells carry stem cell markers as well
as TGF-b markers, including TBRII and b2SP
(TGF-b component Smad3/4 adaptor). Although
Smad3 is expressed ubiquitously, we found that the
common mediator Smad4 is also expressed in this bili-
ary region, perhaps signifying this population as
“committed progenitor cells,” and suggesting that
TGF-b members play multiple and complex roles in
liver stem cell function and in conferring the cell type.
Future lineage tracing experiments will identify the cell
populations responsible for liver regeneration following
injury/damage in the context of TGF-b signaling.
TGF-b, as a pleiotropic cytokine, has been proven
to be differentially involved in the regulation of multi-
lineage differentiation of stem cells (Fig. 5), through
cross-talk involving the Smad pathway, non-Smad
pathways including MAP kinase pathways, PI3K/
AKT pathways, and Rho-like GTPase signaling path-
ways. For instance, TGF-b promotes the
differentiation of stem cells into smooth muscle
cells,(34-37) chondrocytes,(38-40) neurocytes, hepatic
stellate cells, Th17 cells, dendritic cells, and cardio-
myocytes.(41) However, TGF-b inhibits the differenti-
ation of stem cells into myotubes,(42) adipocytes,
endothelial cells, and natural killer cells.(41) Addition-
ally, TGF-b plays a critical role in bone remodeling
and can provide competence for early stages of osteo-
blastic differentiation, but at late stages, TGF-b acts as
an inhibitor.(43,44) In embryonic stem cells (ESCs),
another TGF-b family member, bone morphogenetic
protein (BMP4) is required for ESC self-renewal
through a balanced inhibition of ESC lineage commit-
ment. In mesenchymal stem cells, the BMP signal
induces osteoblastic differentiation through Bmpr1b
but inhibits osteoblastic differentiation through
Bmpr1a.(45) BMP signaling inhibits stem cell activa-
tion and expansion in intestinal stem cells.(46) In
hematopoietic stem cells, BMP signaling through
Bmpr1a restricts stem cell number by controlling the
niche size.(47) In vitro and in vivo studies have demon-
strated that Activin/Nodal signaling maintains pluri-
potency in human pluripotent stem cells(48) and also in
mouse epiblast stem cells.(49) Absence of Nodal signal-
ing results in the loss of pluripotency markers and the
gain of ectopic neuroectoderm marker expression in
the epiblast immediately after implantation.(50,51)
BMP4 through Smad1/5/8 and Activin/Nodal
through Smad2/3 compete to modulate the expression
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FIG. 3. TGF-b/SMAD/CTCF signaling
pathway. The flow chart demonstrates
roles of the TGF-b/b2SP/Smad3/CTCF
signaling pathway in liver stem cell
homeostasis and response to alcohol-
induced injury and inflammation.
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of key pluripotency markers such as Nanog.(52) Activin
B and several other genes that are known to be
involved in enhancing Activin signaling, such as
Wwp2, S100A4, Sulf2, and Inhbb, are also known to
be involved in self-renewal of hair follicle stem cells.(53)
Recently, TRIM33 has been discovered to act as a sig-
nal transducer and direct mediator of transcription in
the TGF-b pathway in ESCs. Ligand activation of
nodal/Activin receptors induces the formation of
TRIM33–Smad2/3 and Smad4–Smad2/3 protein
complexes.(54)
Several TGF-b signaling components are tumor sup-
pressors. Inactivation of at least one of these
components occurs in almost all gastrointestinal
tumors.(17,55) For instance, TBRII is mutated in up to
30% of colon cancers,(56) TBRI is mutated in 15% of
biliary cancers,(57-59) and SMAD4 is deleted in 40%-
60% of pancreatic cancers and mutated in gastrointesti-
nal cancer.(60) Loss of b2SP is observed in human
HCC.(14,61-63) Evidence from Smad4-knockout mice,
which develop head and neck cancers, demonstrates a
significant role for Smad4 in promoting genomic stabil-
ity.(64) Another piece of evidence from studies of liver
regeneration that implicates TGF-b pathway in cancer
involves vitamin D deficiency. Vitamin D supplementa-
tion is essential for TGF-b pathway member expression
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FIG. 4. In human liver regeneration, liver progenitor/stem cells are observed along the pericentral vein early in regeneration (before 6
weeks), and later at the portal tracts (after 6 weeks). As demonstrated colocalization of Oct3/4 and p-Histone, a marker of cell prolif-
eration. Given that hepatocytes primarily drive liver regeneration after acute injury, it is likely that the Oct3/4 and AFP-positive cells
are proliferating hepatocytes and expression of these stem cell markers reflects their stem cell–like nature. More importantly, however,
Oct3/4 and p-Histone–positive cells also colocalize with b2SP and TBRII at all times, as evidenced in the merged images, where
white represents colocalization.
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levels. b-catenin activation in fibrotic/cirrhotic human
liver tissues and vitamin D deficiency promotes tumor
growth in the context of Smad3 disruption, potentially
through the regulation of TLR7 expression and b-
catenin activation. Whole genome and transcriptomic
analyses of somatic mutations and alterations in genes
involved in vitamin D metabolism, vitamin D–related
genes, and the TGF-b superfamily using The Cancer
Genome Atlas database of 147 patients with liver cancer
revealed positive correlation between inactivating somatic
mutations for vitamin D–related genes and the TGF-b
pathway and plays a critical role in liver tumorigenesis.(65)
In addition, TGF-b1 inhibits telomerase activity. Con-
versely, TGF-b1–induced arrest of cell growth can be
overcome by the activation of human TERT, the protein
catalytic subunit of telomerase.(66) Telomerase activation
and maintenance is important for malignant transforma-
tion from normal cells.(67) Keratinocytes cultured from
TGF-b1–null mice have marked genomic instability that
could accelerate tumor progression.(68) More recently,
studies have been conducted in Smad4 conditional
knockout mice that develop head and neck cancers,
where Smad4 has been postulated as a “guardian of the
genome” through regulation of the Fanconi anemia/Brca
(Fanc/Brca) DNA repair pathway.(64,69) Interestingly, the
development of HCCs in b2SP heterozygote mutants
establishes b2SP as a nontraditional and functional tumor
suppressor. Spectrins have been observed to associate
with Fanconi proteins (G and D) as well as with DNA
interstrand cross-links.(70,71) Similarly, by virtue of its
involvement in Smad3/4 localization and subsequent
activation of Smad3/4, b2SP may enhance TGF-b
tumor suppressor function. Also, TGF-b–deficient b2SP
mutant mice are highly susceptible to alcohol injury,
marked by an abnormal response to DNA cross-linking
repair. Taken together, these studies indicate TGF-b as a
potential processor of genomic stability through modula-
tion of the Fanc pathway at interstrand crosslinks, yet
clear mechanisms remain to be elucidated.
TGF-b in Liver Cancer
Stem Cells
Pathways involved in stem cell transformation into
gastrointestinal cancers remain largely undefined and a
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FIG. 5. Summary of mouse knockout and lineage studies on candidate molecules in liver stem cells/cancer stem cells. Data were obtained
from the Mouse Genome Informatics Database. Wnt/Axin: no liver phenotypes were observed, but 65 other phenotypes observed, includ-
ing limb, kidney, and intestine. b-catenin: 341 phenotypes were also observed, including bone and intestinal abnormalities. No liver phe-
notypes were observed. CD133: phenotypes observed included retinitis pigmentosa and retinal degeneration (137). EpCam: no liver
abnormalities were observed, but small intestinal and trophoblast abnormalities were observed. Sox9: No liver phenotypes were observed,
but 184 other phenotypes were observed, including bone, pancreas, and eye abnormalities. LGR5: 12 phenotypes were observed, including
intestinal abnormalities, distended abdomen and neonatal death. In contrast, TGF-b members display definitive foregut-liver lineage and
multiple liver cancer phenotypes. Smad4: 154 phenotypes were observed including ectoderm, mesoderm, no primitive foregut and multiple
gastrointestinal cancers. Smad2/Smad3, b2SP: multiple liver and gastrointestinal abnormalities, and cancers were observed. (M = marker).
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black box. A recent discovery reports that TGF-b–
deficient mutant mice closely resemble a cancer stem
cell disorder, including characteristic ear abnormalities
and adrenal cytomegaly. Beckwith-Wiedemann syn-
drome (BWS) is a human stem cell overgrowth disor-
der with an estimated prevalence of 1 in 14,000(72)
(Fig. 6). The syndrome includes heterogeneous fea-
tures such as organomegaly and adrenal cytomegaly (a
hallmark characteristic)(73) (Fig. 7). BWS is associated
with an 800-fold increased risk of childhood neo-
plasms, and can develop multiple tumor types within
the same organ simultaneously, an example including
the co-occurrence of a mesenchymal hamartoma, capil-
lary hemangioma hepatoblastoma, and cholangiocarci-
noma within the liver of one patient.(74,75) These
events are suggestive of the multipotentiality of neo-
plastic transformation and imply dysfunctional pro-
cesses as stem cells differentiate into mature adult cell
types.(76) Mechanistic insight into downstream effector
pathways which lead to stem cell transformation and
an integrated analysis from mouse models to human
disease for BWS and associated cancers remain only
partially defined.
These new studies demonstrate that TGF-b induces
chromatin insulator CCCTC-binding factor (CTCF)
which facilitates TGF-b–mediated repression of
TERT transcription via interactions with b2SP and
SMAD3. This regulation is abrogated in TGF-b–
defective mice and BWS, resulting in TERT overex-
pression. Tert induction in Sptbn11/2/Smad31/2
mouse embryonic fibroblasts suggests that dysregulated
telomerase expression may be part of the molecular
basis of tumor development in BWS patients. These
results show that recruitment of the SMAD3/b2SP/
CTCF complex at the TERT promoter resulting in
tumorigenesis is dependent on the TGF-b signaling
pathway.(14) Moreover, activation of the SMAD3/
b2SP/CTCF complex on the TERT promoter region
may cooperate with MYC activation. MYC activation
and telomerase dysfunction have been shown to play
prominent roles in early HCC initiation.(77) Therefore,
the TGF-b–mediated b2SP/SMAD3/CTCF complex
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FIG. 6. BWS is a human cancer stem cell overgrowth disorder with an estimated prevalence of 1 in 14,000. The syndrome includes
heterogeneous features such as organomegaly and adrenal cytomegaly (a hallmark characteristic). Sptbn11/2/Smad31/2 mice generated
in the laboratory were phenocopies of BWS patients. Sptbn11/2/Smad31/2 mice demonstrated microfacies and the classic metopic
ridge frequently associated with human BWS and a high risk of cancers that include HCC.
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regulates telomerase activity and is part of a pathway
that suppresses the switch to tumorigenesis in BWS-
associated cancers. Identifying similar key mechanisms
through such mouse models that reflect the human
disease could lead to effective new treatment strategies.
TGF-b in an Invasive
Cancer Stem Cell Model
How chronic inflammation modulates stem cells and
cancer remains only partially defined, and is another
black box. Chronic inflammation, often associated with
liver injury, leads to secretion of cytokines, chemokines,
free radicals, and other DNA-damaging molecules,
thereby changing the hepatic microenvironment.(78)
Persistent inflammation during this long-term process
leads to an expansion of hepatic stem and progenitor
cells that accumulate genetic and epigenetic alterations.
Thus, the highly inflamed liver immune microenviron-
ment is a major driver of the transformation of normal
liver stem cells (LSCs) to highly metastatic cancer stem
cells (CSCs).
Molecular mechanisms that link chronic inflamma-
tory responses with tumor initiation have been studied
extensively.(79,80) Among numerous proinflammatory
factors, interleukin-6 (IL-6) is the most prominently
elevated in almost 40% of liver cancer patients, suggesting
that IL-6 is associated with HCC progression.(81-87) The
TGF-b pathway induced IL-6 secretion may confer
chemotherapeutic resistance in HCC.(32) IL-6 is
required for the priming of hepatocytes to leave their
quiescent state (G0) and enter a prereplicative phase
(G1), and transcriptionally up-regulates an array of
genes during liver growth.(88) A recent study showed
that signal transducer and activator of transcription 3
(STAT3), following its IL-6–mediated activation,
binds to the promoter element of CD133 to induce
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FIG. 7. Identification of cytomegaly of the fetal cortex of the adrenal glands in a b2SP1/2/Smad31/2 mouse (B, D, F) compared
with a wild-type mouse (A, C, E).
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HCC progression.(89) Liver cancer patients with high
levels of CD133 expression have shorter overall sur-
vival and higher relapse rates than those with low levels
of CD133 expression.(90) IL-6–mediated inflamma-
tion programs, constitutive activation of the TGF-b–
activated kinase 1 (TAK1)/nuclear factor kappa B
(NF-jB) signaling cascade in CD1331 LSCs, and
this programming, interacts with deficient TGF-b sig-
naling, thereby accelerating the transformation of nor-
mal LSCs to metastatic CSCs.
CD1331 LSCs derived from preneoplastic livers of
TGF-b–deficient b2SP1/2 mice treated with IL-6
were highly tumorigenic and metastatic and exhibited
nuclear localization of Twist and Slug (markers of
epithelial-mesenchymal transition) and constitutive
activation of NF-jB(91) (Fig. 8). NF-jB was activated
by TAK1 (MAP3K7), which is associated with poor
survival in HCC and IL-6 expression. Hepatocyte-
specific deletion of TAK1 in mice activates the TGF-
b signaling pathway to induce spontaneous inflamma-
tion, fibrosis, and, eventually, hepatic tumorigene-
sis.(92) Overall, this reciprocal regulation between
b2SP and IL-6 in the programming of liver CSCs pro-
vides insight into the mechanism by which normal
stem cells transform into EMT-positive CSCs.(93)
Therefore, these studies demonstrate that there exists a
reciprocal cross-talk between TGF-b signaling and
IL-6–driven inflammation in preneoplastic liver tissues
and defining the mechanisms by which the loss of
TGF-b/b2SP regulates the transition of hepatic stem
cells to cells with EMT phenotypes in an
inflammation-driven hepatic immune environment.
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FIG. 8. Cancer stem cell models of HCC-TGF-b, IL-6. (A) b2SP1/2/Smad31/2 mouse phenocopy of BWS compared with (B)
wild-type mouse. (C) Macroglossia and (D) abnormal anterior ear creases in b2SP1/2/Smad31/2 mice and BWS patients. (E)
b2SP1/2/Smad31/2 mice spontaneously develop liver and gastrointestinal cancers by 12 months of age. (F) Schematic representation
of chronic treatment with IL-6–induced cancer stem cells in b2SP1/2 mice. (G) Orthotopic invasive tumor development after stem
cell inoculation shown in panel F.
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Discovery of this mechanistic insight will improve
modern therapeutic approaches to eliminate metastatic
tumor stem cells at an early stage before tumor initia-
tion and will shed new light on the black box of mech-
anisms of stem cell transformation. Furthermore, this
discovery will provide a scientific basis for a specific
targeted therapy of metastatic CSCs for preventing
invasion, resistance, and relapse.
The Phases of Liver
Regeneration
In the adult liver, mature hepatocytes seldom prolif-
erate and have a life span of over a year.(94) After partial
hepatectomy, however, proliferation of the normally
quiescent hepatocytes and cholangiocytes, followed by
proliferation of the hepatic stellate cells and endothelial
cells quickly restores the liver to its original mass. In
the rodent model, DNA synthesis starts 12 to 16 hours
after the standard partial hepatectomy (PHx) and
peaks at 24-48 hours. The original organ mass is
almost restored 3-7 days postresection, and by 3-4
months in humans.(95,96) Liver regeneration therefore
represents an example of precisely controlled initiation
and synchronized cell proliferation in vivo, in which
normally quiescent hepatocytes exit G0, reenter the
cell cycle, and undergo one or two rounds of replica-
tion, with restoration of liver mass and func-
tion.(94,97,98) The initiation step is characterized by
priming of quiescent hepatocytes by factors such as
tumor necrosis factor a (TNF-a), IL-6, and nitric
oxide. These cytokines are released within minutes of
partial hepatectomy from nonparenchymal liver cells
and induce hepatocytes to synthesize further acute
phase proteins—mainly protease inhibitors—through
activation of hepatocyte DNA-binding proteins.(99,100)
Therefore, more than 100 immediate early genes are
activated by latent transcription factors at the transition
between G0 and G1. For instance, within minutes,
specific transcription factors such as NF-jB, STAT3,
and AP1 are rapidly activated in remnant hepatocytes,
as are intracellular signaling pathways such as
mitogen-activated protein kinase, phosphorylated
extracellular signal-regulated kinases, and Jun amino-
terminal kinase.(101-103) The result is an induction of
hepatocytes to become sensitive to growth factors and
competent for replication.
The proliferation step arises when hepatocytes enter
the cell cycle as G1 phase and are stimulated by com-
plete mitogens including hepatocyte growth factor
(HGF). HGF increases 10- to 20-fold in the plasma
within the first 3 hours after PHx and activates the
HGF receptor cMet within 30-60 minutes.(104,105)
Similarly, plasma concentration of TNF-a, IL-6, epi-
dermal growth factor, and TGF-b1 increase within 1-
2 hours after PHx. These hepatomitogens, together
with co-mitogens such as norepinephrine and potenti-
ating factors such as insulin, induce hepatocytes to
override the mitogen restriction point at two-thirds of
the G1 phase and progress into DNA synthesis. These
factors induce cyclins and cyclin-dependent kinases
that play critical roles in cell cycle progression.(106-108)
Intracellularly, b-catenin and the Notch1 intracellular
domain translocate to hepatocyte nuclei within 15-30
minutes, and enhanced activation of STAT3 and NF-
jB within 1 hour contributes to activation of signaling
pathways leading to cell cycle progression.
Cell cycle progression, regulated by the sequential for-
mation, activation, and inactivation of complexes com-
posed of cyclin-dependent kinases (Cdks) and cyclins
proceeds in a synchronized pattern following PHx. In
mid- to late G1, phosphorylation of the retinoblastoma
protein by Cdk4/6-cyclin D complexes initiates the cell
cycle and mediates the G1/S-phase transition.(109) Cdk2
then successively associates with cyclins E and A, com-
pletes phosphorylation of retinoblastoma protein, pro-
motes activation of the DNA replication machinery, and
regulates centrosome duplication, completing transition
into S-phase. Cdk1, in association with cyclins A and B,
is then essential for entry and exit from mitosis. Cyclin
D1 has been shown to be activated by 6 hours and maxi-
mal levels of Cdk4 are present at 24 hours after PHx in
rats.(110) Meanwhile, Cdk1 is sharply induced between
18 and 24 hours, followed by a transient decrease, before
another increase at 30 hours post-PHx in rats.(111)
Regeneration is complete, when an appropriate func-
tional size is reached. TGF-b plays a prominent role in






Insight Into Their Function
TGF-b signaling has been shown to reversibly
inhibit the proliferative response following partial
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hepatectomy.(112) TGF-b1 levels are raised in the first
2 hours after PHx, and expression levels of down-
stream Smads, phospho-Smad2, Smad2, and Smad4
are similarly elevated.(95,113) Concomitant up-
regulation of TGF-b inhibitory proteins, SnoN and
Ski, and a down-regulation of the TGF-b receptors,
allows hepatocytes to transition from G1 to S
phase.(114) TBRII-conditional knockout mice demon-
strate accelerated proliferation and an increased liver
mass to body weight ratio after PHx.(115)
TGF-b is primarily synthesized by stellate cells, a
cell type that resides within the space of Disse (perisi-
nusoidal space) in recesses between hepatocytes. There
are approximately 2-20 stellate cells per 100 hepato-
cytes, and these are activated during liver injury and
become myofibroblasts that produce extracellular
matrix, leading to progression of fibrosis and liver
disease in the aberrant state. TGF-b released from
these stellate cells has a paracrine effect on hepatocytes.
TGF-b perturbations occur primarily in hepatocytes or
stellate cells, depending on which cell type is domi-
nantly undergoing proliferative changes after liver
injury. Each isoform of TGF-b has its own character-
istic pattern of messenger RNA (mRNA) expression
(which is assumed to have a high degree of correlation
to secreted protein levels(116)) during a 72-hour period
after PHx (Figs. 9 and 10).(116) The early phase of
TGF-b1 expression (2- to 6-hour time point) precedes
the major peak of hepatocyte growth, while the 48- to
72-hour time point coincides with the decrease in liver
cell turnover.(116) The b1 isoform has an early peak at
2 hours, but then decreases and spikes again between
48 and 72 hours in hepatocytes. This suggests that the
b1 isoform probably plays two different roles in liver
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FIG. 9. TGF-b–associated genes had a characteristic pattern of mRNA expression during a 72-hour period after PHx. Core TGF-b
pathway–related genes were evident in liver regeneration.
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regeneration: a major role both during the initial phase
as liver regeneration progresses to DNA synthesis, as
well as role in the later, termination phase of liver
regeneration after injury. The b2 isoform is increased
in all liver cell types at hour 6, but at the later time
point, the hepatocyte fraction shows a further increase,
whereas the nonparenchymal cell fractions decline.
The b3 isoform shows major increases in all cell frac-
tions at the early time point, but only the hepatocyte
fraction maintains this increase at the later time
point.(116,117)
Levels of TBRI and TBRII involved in TGF-b sig-
naling are decreased in the early liver regeneration
phase while TBRIII and TGF-bRAP1/TRAP1 which
are known to be inhibitors of TGF-b signaling(118,119)
are elevated. These expression levels are reversed in
correlation to TGF-b peaks in the 6- and 72-hour
phases. Bone morphogenetic proteins (BMPs) are
members of the TGF-b family and act as constitutively
expressed repressors of regeneration. Consistent with
this hypothesis, BMPs are expressed in the initial
phase within 2 hours and then down-regulated as
TGF-b spikes.(116,120) In the normal liver, strong
BMP2 expression is observed around the central and
portal veins. The observed down-regulation of BMP2
in rat liver following partial hepatectomy suggests that
such down-regulation may be necessary for hepatocyte
proliferation.(121) Mice driven to maintain BMP4
expression in the liver, display inhibited hepatocyte
proliferation and restoration of liver mass after
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FIG. 10. mRNA expression of other TGF-b pathway–related genes was evident in liver regeneration during a 72-hour period after
PHx.
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hepatectomy, suggesting that reduced BMP4 is neces-
sary for normal regeneration.(120) Consistent with this
finding, the BMP receptors also follow an inverse pat-
tern of up-regulation compared with TGF-b activation
and are mostly up-regulated in the anti-proliferative/
termination phase.(116)
Hepatocyte-specific deletion of the BMP receptor
Activin receptor-like kinase 3 enhances regenera-
tion.(120) The BMP4 antagonist Noggin has also been
reported to enhance regeneration. BMP7 expression is
absent in liver; however, neutralization of circulating
endogenous BMP7 results in significantly impaired
regeneration of the liver after partial hepatectomy,
whereas therapeutic administration of recombinant
human BMP7 significantly enhances liver regeneration.
BMP9 stimulation of cultured hepatocytes inhibited
proliferation. Constitutive expression of low levels of
BMP9 stabilizes hepatocyte function in the healthy
liver. Acute liver injury caused by partial hepatectomy
results in transient down-regulation of hepatic BMP9
mRNA expression and following HSC activation,
endogenous BMP9 levels again increase.(122) Regulation
of Activin signaling through receptors is another major
factor determining liver regeneration after liver injury.
Activins inhibit DNA synthesis in hepatocytes and
Activin and their receptors are initially down-regulated
and later induced between 24 and 72 hours after the
proliferation slows down.(123) Likewise, Inhibins which
have biological effects directly opposite to those of Acti-
vins are induced in the initial phase, down-regulated
when Activins are up-regulated, and elevated again in
the later phase when activin expression is reduced.(116)
Smad proteins are intracellular effectors of TGF-b
signaling and transduce signals from TGF-b superfamily
ligands that regulate cell proliferation, differentiation and
death through activation of receptor serine/threonine
kinases. Partial hepatectomy stimulates a strong regener-
ative response with elevated expression of Smad2/3
phosphorylation in the first 2 hours followed by IL-6,
TNF-a, and STAT3 induction 24 hours post-PHx in
both hepatocytes and nonparenchymal cells.(116,124)
Smad3 deficiency leads to reduced hepatocyte prolifera-
tion 42 hours post-PHx, a process that correlated with
and was preceded by significant reductions in IL-6
expression and STAT3 phosphorylation. STAT3, upon
activation by a number of factors including IL-6, regu-
lates cell survival and proliferation and liver regeneration
and loss of STAT3 in hepatocytes reduces their prolifer-
ation early during regeneration after PHx.(125,126)
Among the other SMADs, suppression of SMAD1,
SMAD5, and SMAD9 is known to repress liver
regeneration.(127) SMAD6 inhibits Wnt/b-catenin
signaling and suppresses the growth and self-renewal
of hepatic progenitor cells.(128) Adaptors such as b2
spectrin (b2SP) are involved in hepatocyte prolifera-
tion through the interaction of TGF-b/Smad and
PI3K/AKT signaling.(129) b2SP deficiency results in
dysfunctional hepatocyte cell cycle progression and
delayed liver regeneration at 48 hours after PHx. This
defect is mediated by dysfunctional expression of cell
cycle proteins and by increased DNA damage.(27) Spa-
tial and temporal expansion of TBRI and b2SP
expression occurs as regeneration proceeds. TBRI and
b2SP expression increases gradually in the initial
phase, until approximately 18 hours after hepatic
injury, and then decreases.(116) The spatial expansion
of TBRI and b2SP proceeds from periportal to peri-
central areas of lobules, suggesting an important role
for the TGF-b signaling molecules in liver regenera-
tion in response to liver injury.(28) An interesting tran-
sition between PRAJA (PJA1), an E3-dependent
ubiquitin ligase of b2SP, and b2SP proteins, occurs at
6 hours postinjury, with expression of PJA1, and b2SP
predictably inversely proportional to each other. At 6
hours, PJA1 levels begin to decrease, allowing the up-
regulation of b2SP on a background of TGF-b expres-
sion, which is already high compared with expression
in normal liver. As PJA1 expression continues to
decrease over 6-12 hours postinjury, b2SP remains
accumulated in the cells.(130) Potentially targeting sim-
ilar E3 ligases that are activated in the setting of loss of
TGF-b tumor suppressor activity, could provide
attractive new therapeutics for HCC.
Serial transplantation experiments have shown that
hepatocytes have a near infinite capacity to prolifer-
ate.(94,131,132) When mature hepatocytes and cholan-
giocytes are damaged or inhibited in their replication,
however, a reserve compartment of hepatic progenitor
cells are activated.(133) In human liver donor transplant
recipients, early on within the first 6 weeks, expansion
of cells expressing stem cell markers Oct3/4, AFP, and
TGF-b members is observed in zone 1, zone 2,(28) and
surprisingly also zone 3 (central vein)(134-136) and
appears to give rise to hepatocytes. These studies sug-
gest that in submassive hepatic necrosis with intact
zones 1 and 2, cells express stem cell markers and
potentially lead the regenerative process.(28,33) The
activation of the stem cell compartment, originally
referred to as a “ductular reaction” in humans and “oval
cell reaction” in rodents, is observed in circumstances
of prolonged necrosis, cirrhosis, and chronic inflamma-
tory liver diseases. In summary, rodent studies have led
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to the identification of the three stem cell compart-
ments displayed by markers of the Wnt/Axin/Lgr5
family, EpCam, and CD133. Yet mouse mutants of
the single gene knockouts do not reveal significant liver
pathology (Fig. 5). Mouse knockouts, human liver
regeneration, and functional studies thus reveal a piv-
otal role for TGF-b in suppressing cancer stem cells,
as well as modulating processes of liver regeneration
and fibrosis.(27,28) However, exactly how it is defined
temporally with existing stem cell markers such as
Axin1, Lgr5, Fancd2, and CD133 remains to be
explored. Importantly, the studies provide a key role
for the TGF-b pathway in suppressing cancer stem
cells, and the loss of TGF-b signaling in these cells
could lead to better identification of these cells, as well
as prediction of tumor behavior and ultimately lead to
precise targeting of cancer stem cells in this lethal
cancer.
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